Daxor (NASDAQ:DXR – Get Free Report) had its target price upped by Ascendiant Capital Markets from $24.75 to $25.00 in a research report issued on Monday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. Ascendiant Capital Markets’ price target would suggest a potential upside of 205.62% from the stock’s current price.
Daxor Stock Performance
DXR stock opened at $8.18 on Monday. Daxor has a 52 week low of $6.55 and a 52 week high of $10.00. The company’s 50-day simple moving average is $7.79 and its 200 day simple moving average is $8.49.
Insiders Place Their Bets
In related news, CEO Michael Richard Feldschuh bought 3,360 shares of the business’s stock in a transaction dated Monday, March 10th. The stock was purchased at an average cost of $7.68 per share, for a total transaction of $25,804.80. Following the transaction, the chief executive officer now owns 210,852 shares in the company, valued at $1,619,343.36. The trade was a 1.62 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 59.00% of the company’s stock.
Institutional Inflows and Outflows
About Daxor
Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions.
Recommended Stories
- Five stocks we like better than Daxor
- How to trade using analyst ratings
- Meta Platforms: Can LLaMA Drive Long-Term Stock Growth?
- How is Compound Interest Calculated?
- 3 Unique and Dominant Consumer Staples ETF Plays
- How to Calculate Stock Profit
- 3 Dividend Stocks Offering Higher Yields and Bullish Forecasts
Receive News & Ratings for Daxor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Daxor and related companies with MarketBeat.com's FREE daily email newsletter.